Autres langues DURECT Corporation Deutsche Boerse AG

Actions

DC8A

US2666055007

Marché Fermé - Deutsche Boerse AG Autres places de cotation 21:50:00 17/07/2024			Varia. 5j.	Varia. 1 janv.
1,28 ^EUR	+6,67 %		+7,56 %	+143,81 %

21/05	DURECT Corporation reçoit de la FDA la désignation de thérapie révolutionnaire pour le larsucostérol dans le traitement de l'hépatite associée à l'alcool	CI
21/05	Mise à jour sectorielle : Les actions du secteur de la santé en hausse mardi après-midi	MT

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis	21/05
Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon	21/05
Durect Gets FDA Breakthrough Therapy Designation for Alcohol-Related Hepatitis Treatment	21/05
DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis	21/05
Durect Far From Earnings Story But FDA Commentary Shows Path Forward, Oppenheimer Says	14/05
Durect: Q1 Earnings Snapshot	13/05
DURECT Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Earnings Flash (DRRX) DURECT CORPORATION Reports Q1 Revenue $1.8M, vs. Street Est of $2.7M	13/05
DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update	13/05
DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update	07/05
DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis	30/04
Durect: Q4 Earnings Snapshot	27/03
DURECT Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Earnings Flash (DRRX) DURECT CORPORATION Posts Q4 Revenue $2.7M, vs. Street Est of $2.7M	27/03
DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	27/03
DURECT Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	27/03
North American Morning Briefing : Stocks Edge -2-	27/03
DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update	20/03
North American Morning Briefing : Stock Futures -2-	19/03
DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada	04/03

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues DURECT Corporation Deutsche Boerse AG

Actions

DC8A

US2666055007

Autres langues

Filtres